Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with newly diagnosed acromegaly~* age above 18 years~* no previous treatments for acromegaly~Exclusion Criteria:~* primary surgery~* concomitant hyperprolactinemia if requiring combined treatment with dopamine-agonist~* primary treatment with lanreotide~* treatment duration less than 24 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).